Linperlisib

Phase 2Small molecule

SShanghai YingLi Pharmaceutical Co. Ltd.

Linperlisib is one of 86 small molecule programs targeting Hemolytic Anemia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hemolytic AnemiaActive, not recruiting

LymphomaActive, not recruiting

LeukemiaActive, not recruiting

Hemolytic AnemiaPhase 1

Active, not recruiting

LymphomaPhase 2/Phase 3

Active, not recruiting

LeukemiaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 2

Linperlisib

SShanghai YingLi Pharmaceutical Co. Ltd.

Phase 2

6 3

Velban

EEastern Cooperative Oncology Group

Preclinical

15 4

Norvir

AbbVie

Preclinical

1 5

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 6

Nuvigil

NNuvo Research GmbH

Preclinical

1 7

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 8

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 9

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—10

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Not yet recruiting

Treatment

NCT07031115

Q1 2027

Phase 1/2Not yet recruiting

Lymphoma

NCT07209163

Q2 2027

Phase 2Recruiting

Relapsed/refractory

NCT06489808

Not yet recruiting

Lymphoma

NCT05863871

Q4 2027

Phase 1/2Recruiting

Lymphoma

NCT06376721

Clinical

Trials by Indication[1]

Lymphoma6 trials

Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma

Recruiting·—·Phase 1/2·NCT06376721·43 enrolled

Combination Therapy With Tazemetostat in Relapsed and Refractory Peripheral T-cell Lymphoma

Not yet recruiting·RRuijin Hospital·Phase 1/2·NCT07209163·48 enrolled

A National Multicenter, Real-world Study of Linperlisib in the Treatment of Lymphoma

Not yet recruiting·SShanghai YingLi Pharmaceutical Co. Ltd.·Phase 4·NCT06343935·88 enrolled

Show 3 more trials

Real World Study of Linperlisib for Lymphoma Treatment

Not yet recruiting·RRuijin Hospital··NCT05863871·1,000 enrolled

Linperlisib Combined With Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma

Not yet recruiting·SSun Yat-sen University·Phase 1/2·NCT07139353·54 enrolled

A Phase II/III Study of Linperlisib Plus CHOP Versus CHOP in Patients With Newly Diagnosed Peripheral T Cell Lymphoma

Not yet recruiting·SShanghai YingLi Pharmaceutical Co. Ltd.·Phase 2/3·NCT06548347·606 enrolled

Leukemia2 trials

Efficacy and Safety of Linperlisib in Relapsed/Refractory Large Granular T Lymphocytic Leukemia

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT06224257·41 enrolled

Efficacy and Safety of PI3K Inhibitors in Relapsed/Refractory Large Granular T Lymphocytic Leukemia

Completed·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1·NCT05676710·8 enrolled

PTCL1 trial

A Umbrella Study in R/R PTCL Guided by Molecular Subtypes

Unknown status·RRuijin Hospital·Phase 1/2·NCT05559008·116 enrolled

Relapsed/Refractory1 trial

Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT06489808·89 enrolled

Treatment1 trial

Linperlisib in the Treatment of aPRCA

Not yet recruiting·PPeking Union Medical College Hospital·Phase 2·NCT07031115·15 enrolled

2 more indications

Hemolytic Anemia1 trial

PI3K Delta Inhibitor in Relapsed / Refractory Autoimmune Hemolytic Anemia Patients After Receiving Two or More Lines of Therapy

Terminated·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1·NCT05676697·4 enrolled

Camrelizumab1 trial

A Study of Linperlisib Combination With Camrelizumab in Patients With Solid Tumor

Unknown status·SShanghai YingLi Pharmaceutical Co. Ltd.·Phase 1·NCT05429398·118 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for Linperlisib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Linperlisib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Linperlisib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai YingLi Pharmaceutical Co. Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SShanghai YingLi Pharmaceutical Co. Ltd.

Linperlisib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q2 2027

Q4 2027

Trials by Indication[1]

Lymphoma6 trials

Leukemia2 trials

PTCL1 trial

Relapsed/Refractory1 trial

Treatment1 trial

Hemolytic Anemia1 trial

Camrelizumab1 trial

References

Drug Info

Quick Facts

Related News